Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8223510rdf:typepubmed:Citationlld:pubmed
pubmed-article:8223510lifeskim:mentionsumls-concept:C0008625lld:lifeskim
pubmed-article:8223510lifeskim:mentionsumls-concept:C0008626lld:lifeskim
pubmed-article:8223510lifeskim:mentionsumls-concept:C0949775lld:lifeskim
pubmed-article:8223510lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:8223510lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:8223510lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:8223510pubmed:issue4lld:pubmed
pubmed-article:8223510pubmed:dateCreated1993-12-21lld:pubmed
pubmed-article:8223510pubmed:abstractTextEvidence is provided that antitopoisomerase drugs induce chromosomal aberrations via the formation of DNA double strand breaks. Camptothecin, an inhibitor of DNA topoisomerase I, produced only chromatid-type aberrations, and in order to be effective it has to be present during the DNA replication. The fact that it induces chromosomal aberrations also in the G2 phase of the cell cycle suggests the presence of a residual DNA synthesis in this phase. A pretreatment with aphidicolin, an inhibitor of DNA polymerases, reduces the camptothecin induced aberrations in the G2 phase, confirming the need of DNA synthesis for the induction of aberrations by the inhibitor of DNA topoisomerase I.lld:pubmed
pubmed-article:8223510pubmed:languageenglld:pubmed
pubmed-article:8223510pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8223510pubmed:citationSubsetIMlld:pubmed
pubmed-article:8223510pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8223510pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8223510pubmed:statusMEDLINElld:pubmed
pubmed-article:8223510pubmed:issn0893-6692lld:pubmed
pubmed-article:8223510pubmed:authorpubmed-author:PalittiFFlld:pubmed
pubmed-article:8223510pubmed:issnTypePrintlld:pubmed
pubmed-article:8223510pubmed:volume22lld:pubmed
pubmed-article:8223510pubmed:ownerNLMlld:pubmed
pubmed-article:8223510pubmed:authorsCompleteYlld:pubmed
pubmed-article:8223510pubmed:pagination275-7lld:pubmed
pubmed-article:8223510pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:8223510pubmed:meshHeadingpubmed-meshheading:8223510-...lld:pubmed
pubmed-article:8223510pubmed:meshHeadingpubmed-meshheading:8223510-...lld:pubmed
pubmed-article:8223510pubmed:meshHeadingpubmed-meshheading:8223510-...lld:pubmed
pubmed-article:8223510pubmed:meshHeadingpubmed-meshheading:8223510-...lld:pubmed
pubmed-article:8223510pubmed:meshHeadingpubmed-meshheading:8223510-...lld:pubmed
pubmed-article:8223510pubmed:meshHeadingpubmed-meshheading:8223510-...lld:pubmed
pubmed-article:8223510pubmed:meshHeadingpubmed-meshheading:8223510-...lld:pubmed
pubmed-article:8223510pubmed:year1993lld:pubmed
pubmed-article:8223510pubmed:articleTitleMechanism of induction of chromosomal aberrations by inhibitors of DNA topoisomerases.lld:pubmed
pubmed-article:8223510pubmed:affiliationDipartimento di Agrobiologia e Agrochimica, Università Degli Studi Della Tuscia, Viterbo, Italy.lld:pubmed
pubmed-article:8223510pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8223510pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8223510lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8223510lld:pubmed